greater reimbursement than radical prostatectomy. While these analyses are always limited by the assumptions made by the authors, it does suggest that in a fee-forservice environment, urologists may actually have an incentive not to operate. Ultimately, how this will all change in universal health care of course remains to be seen.
The search for biomarkers of prostate cancer continues, with a study in this issue showing that C-myc, which is frequently upregulated in prostate cancer, is correlated with prostate cancer progression. C-myc is an interesting gene in that it is clearly a proto-oncogene, but has a crucial role in cellular metabolism and facilitates tumor cell survival by upregulating glycolysis among other pathways. This in turn suggests that nutritional approaches may inhibit tumor growth. To test this, in another paper in this issue, a particular group used an intermittent fasting approach to limit glucose delivery to the tumor to slow tumor growth. Contrary to their earlier results in a pilot study, this time the authors found no effect on tumor growth. They concluded that intermittent fasting in the absence of total caloric restriction imparted no effect on tumor growth. This is an important message for all of those people who routinely go from diet to diet and lose weight but then gain it all back between diets, namely, this may not be the most effective way to inhibit tumor growth.
Prostate cancer patients tend to be very interested in nutritional supplements. Of the supplements studied, curcumin appears to be one of the more interesting. In this issue of the journal, Choi et al. show that curcumin interrupts an important cellular interaction between androgen receptor signaling and the Wnt/beta-catenin pathway. As we all know, androgen signaling is crucial for prostate cancer growth. Thus, the concept that a lowtoxicity natural compound like curcumin could interfere with signaling in this crucial pathway is important and supports a growing body of evidence that natural compounds in general and curcumin in specific may be useful for treatment of prostate cancer.
In summary, I hope you enjoy this issue of the journal. To all, I wish you happy holidays and a happy 2011. See you next year!
SJ Freedland
Editor
